Heartware International (HTWR -7%) slips after reporting a Q2 EPS loss of $0.79 versus the estimated $0.78, missing by $0.01.
EPS were Up 51% from the same quarter last year.
Revenue came in at $50.80M, +75% Y/Y.
Revenue from international markets, generated through the sale of 288 units, was $25.7M, +4% Y/Y.
R&D costs rose nearly 25% to $24.2M, primarily due to clinical trial costs related to advancing its pipeline technologies.